Market Overview

The Europe Dry Eye Syndrome Market was valued at USD 792.0 Million in 2024 and is expected to reach USD 1,168.5 Million by 2033, exhibiting a CAGR of 4.4% during the forecast period 2025-2033. Market growth is driven by an aging population, rising digital device usage, and environmental factors such as pollution and low humidity. Increasing awareness of eye health, advanced diagnostics, and access to innovative treatments are boosting demand.

Study Assumption Years

  • Base Year: 2024
  • Historical Years: 2019-2024
  • Forecast Period: 2025-2033

Europe Dry Eye Syndrome Market Key Takeaways

  • The Europe dry eye syndrome market size was valued at USD 792.0 Million in 2024.
  • It is projected to reach USD 1,168.5 Million by 2033 with a CAGR of 4.4% from 2025 to 2033.
  • Aging population in Europe leads to decreased tear production and higher susceptibility to ocular disorders such as cataracts, glaucoma, and diabetes, driving market growth.
  • Increased digital screen exposure reduces blink rate causing dry eye syndrome, notably impacting younger populations and working professionals.
  • Innovations in treatment options, including prescription drugs and minimally invasive procedures, alongside improved healthcare infrastructure, support market expansion.

Sample Request Link: https://www.imarcgroup.com/europe-dry-eye-syndrome-market/requestsample

Market Growth Factors

The growth of the dry eye syndrome market in Europe is expected to increase, due to an increase in the aging population, resulting in a decrease in tear production and a degradation of the ocular surface․ Older patients are more likely to have dry eye syndrome and comorbidities such as cataracts, glaucoma and diabetes mellitus․ This geriatric demographic, which requires more treatment options such as artificial tears and prescription drugs, will remain a dominant factor in the growth of the market․

Dry eye syndrome is an emerging health concern across Europe as screen use increases․ More time in front of a screen reduces frequency of blinking, leading to faster evaporation․ Those living in urban areas with air conditioning and pollution can have even more serious symptoms․ Since the problem of dry eye syndrome also affects young professionals, the demand for preventatives and treatments like lubricating eye drops and inserts has been increasing․

Increased adoption of treating dry eye disorder through prescription of novel therapies- cyclosporine-based eye drops, lifitegrast solutions, thermal pulsation devices for improved outcomes and treatment adherence- is expected to propel the market growth over the forecast period․ Favorable healthcare infrastructure for diagnosis and treatment in Europe creates an opportunity for the regional market․ Governmental programs encouraging eye health, insurance coverage which makes therapies cheaper for consumers, and research and development (R&D) investments by pharmaceutical companies in targeted therapies drive growth in this segment․

Market Segmentation

By Disease Type:

  • Evaporative Dry Eye Syndrome: Dominates the market due to high prevalence linked to meibomian gland dysfunction and lifestyle factors such as prolonged digital screen usage, air-conditioned settings, and pollution. Availability of targeted treatments like lipid-based eye drops and thermal pulsation devices has increased adoption.
  • Aqueous Dry Eye Syndrome

By Drug Type:

  • Anti-inflammatory Drugs: Hold the largest share as they target the underlying chronic inflammation causing DES, improving outcomes especially in moderate to severe cases. Prescription corticosteroids and immunomodulatory treatments are increasingly preferred.
  • Lubricant Eye Drops
  • Autologous Serum Eye Drops

By Product:

  • Liquid Drops: Most popular due to ease of use, immediate relief, affordability, and suitability across all ages and severities. Advancements in preservative-free and enhanced viscosity formulations improve comfort and adherence.
  • Gel
  • Liquid Wipes
  • Eye Ointment
  • Others

By Distribution Channel:

  • Hospital Pharmacies: Lead market share due to frontline role in diagnosis and management of moderate to severe cases, offering prescription therapies and benefiting from established supply chains and insurance integration.
  • Retail Pharmacies
  • Online Pharmacies

Regional Insights

Germany is the dominant market in Europe for dry eye syndrome due to its advanced healthcare infrastructure, high awareness of ocular health, and growing aging population. The country benefits from strong diagnostic capabilities and access to innovative treatments, significantly contributing to the region’s market growth. Other notable markets include France, the United Kingdom, Italy, and Spain, each driven by rising digital device usage, aging demographics, and supportive healthcare policies.

Recent Developments & News

In July 2025, INEYE THERAPEUTICS, S.A. raised €600,000 to advance ocular drug delivery methods for dry eye treatment. In May 2025, Alcon received U.S. FDA approval for TRYPTYR acoltremon ophthalmic solution, a novel therapy for DES. April 2025 saw Sigmapharm launch Carragelose-based coldamaris protect eye drops in Austria, while Nordic Pharma secured CE mark authorization for Lacrifill, enabling its launch across Europe.

Key Players

  • INEYE THERAPEUTICS, S.A.
  • Alcon
  • Marinomed Biotech
  • Sigmapharm
  • Nordic Pharma

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.